moksha8 Launches Broad Product Portfolio in Key Emerging Markets, Strategic Alliances with Roche and Pfizer Provide Portfolio of Over 20 Products
moksha8, Inc. announced today strategic partnerships with Roche and Pfizer, the launch of over twenty products and establishment of its Latin America headquarters in Sao Paulo, Brazil. moksha8 is committed to providing the highest quality medicine to the fastest growing markets of the world, with an initial focus on Asia, Latin America and Eastern Europe.
In February 2008, moksha8 established strategic alliances with Roche and Pfizer in four therapeutic areas, CNS disease, anti-infectives, cardiovascular disease and pain management. The initial Roche and Pfizer portfolios consist of more than 20 products, including Neurontin®, Lexotan®, Zoloft®, and Bactrim®
moksha8 has established its Latin American headquarters in Sao Paulo, Brazil and has built a fully integrated sales and marketing team to drive the launch and commercialization of this comprehensive first line of products. Current annual sales of these products in Brazil are estimated to be over $80 million USD.
COPYRIGHT © 2006-2018 MOKSHA8 PHARMACEUTICALS, INC. ALL RIGHTS RESERVED. THIS INFORMATION—INCLUDING PRODUCT INFORMATION—IS INTENDED ONLY FOR RESIDENTS OF THE UNITED STATES. THE PRODUCTS DISCUSSED HEREIN MAY HAVE DIFFERENT LABELING IN DIFFERENT COUNTRIES.